Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4

Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4

Abstract Background: Antibodies and derivative drugs targeting immune checkpoints have been approved for the treatment of several malignancies, but there are fewer responses in patients with pancreatic cancer. Here, we designed a nanobody molecule with bi-targeting on PD-L1 and CXCR4, as both target...

Full description

Bibliographic Details
Main Authors: Shuai Hao, Shuyi Xu, Liangzhu Li, Yaxian Li, Meiqi Zhao, Junsheng Chen, Shunying Zhu, Yueqing Xie, Hua Jiang, Jianwei Zhu, Mingyuan Wu
Format: Article
Language:English
Published: BMC 2022-10-01
Series:BMC Cancer
Subjects:
PD-L1
CXCR4
Antibody
Bispecific nanobody
Immunotherapy
Pancreatic cancer
Online Access:https://doi.org/10.1186/s12885-022-10165-7

Similar Items

Similar Items